In a recent study, gepotidacin, an investigational oral antibiotic, showed 92.6% microbiological success in treating uncomplicated urogenital gonorrhea, demonstrating noninferiority to standard injectable therapy. The trial compared two oral doses of gepotidacin with the standard regimen of a single intramuscular dose of ceftriaxone plus oral azithromycin, concluding that gepotidacin was a potential oral treatment option given current concerns about antimicrobial resistance.

Source: The Lancet